Atlas Venture, an early stage venture capital firm investing in biotech innovation, has closed its thirteenth fund, raising USD450 million in an oversubscribed fundraise.
With Fund XIII, Atlas Venture will continue working alongside talented entrepreneurs to create and invest in a new set of biotech companies aimed at delivering impactful medicines to patients.
Atlas Venture has been building and investing in innovative biotech startups for more than two decades. Since 2015, Atlas Venture has raised over USD2 billion and has created and/or invested in over 50 biotech companies. In addition to Fund XIII, Atlas is also investing from Opportunity Fund II, a USD300 million fund raised in 2021 to support portfolio companies as they raise subsequent financings and advance therapeutic programs. Alongside Atlas partner Jason Rhodes, the six investing partners in Fund XIII also include Kevin Bitterman, Bruce Booth, Jean-François Formela, Michael Gladstone, and David Grayzel.
